Biology:Interleukin 36 receptor antagonist

From HandWiki
Short description: Protein-coding gene in the species Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

Interleukin 36 receptor antagonist (IL-36RA) is a member of the interleukin-36 family of cytokines. It was previously named Interleukin-1 family member 5 (IL1F5).[1][2][3][4]

The protein is known to inhibit the effects of Interleukin-36 cytokines (IL-36α, IL-36β and IL-36γ) via competing with their receptor IL-36R/IL1RL2 and thereby inhibiting their proinflammatory effects.[5]

Roles in disease

Mutations in the IL-36RN gene resulting in a decrease or production of defective IL-36RA protein have been shown to cause inflammatory skin diseases including generalised pustular psoriasis, acrodermatitis continua suppurativa Hallopeau (ACH) and acute generalized exanthematous pustulosis (AGEP).[6]

References

  1. "Four new members expand the interleukin-1 superfamily". J Biol Chem 275 (2): 1169–75. Feb 2000. doi:10.1074/jbc.275.2.1169. PMID 10625660. 
  2. "IL1HY1: A novel interleukin-1 receptor antagonist gene". Biochem Biophys Res Commun 263 (3): 702–6. Nov 1999. doi:10.1006/bbrc.1999.1440. PMID 10512743. 
  3. "A new nomenclature for IL-1-family genes". Trends Immunol 22 (10): 536–7. Sep 2001. doi:10.1016/S1471-4906(01)02040-3. PMID 11574262. 
  4. "Entrez Gene: IL36RN interleukin 36 receptor antagonist". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=26525. 
  5. Towne, JE; Garka, KE; Renshaw, BR; Virca, GD; Sims, JE (2 April 2004). "Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs.". The Journal of Biological Chemistry 279 (14): 13677–88. doi:10.1074/jbc.M400117200. PMID 14734551. 
  6. Navarini, AA; Valeyrie-Allanore, L; Setta-Kaffetzi, N; Barker, JN; Capon, F; Creamer, D; Roujeau, JC; Sekula, P et al. (July 2013). "Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis.". The Journal of Investigative Dermatology 133 (7): 1904–7. doi:10.1038/jid.2013.44. PMID 23358093. 

Further reading